Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human BMS-986218 alone and with nivolumab in advanced solid tumors
NL-OMON54185Phase 1Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BMS-986218, nivolumab and ipilimumab in Nonhematologic neoplasms, cutaneous melanoma (CM), non-small cell lung cancer (NSCLC) and 1 more (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability, Dose-limiting toxicities and 5 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasmscutaneous melanoma (CM)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON54185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54185.